Market News (Page 1) - TendieTensor

Market News Page 1 of 178 • 4,441 articles

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

12/06/2025 02:55 PM • Rosen Law Firm is investigating potential securities claims for Alvotech shareholders following an FDA Complete Response Letter for their Biologics License Application, which caused a significant stock price drop.

SOXX - Semiconductor stocks tracked by the ETF dropped 7.4% for the week
ALVO - The company received a Complete Response Letter from FDA for AVT05, resulting in a 34% stock price drop on November 3, 2025, and an additional 4% decline on November 4, 2025. The FDA noted unresolved deficiencies in their manufacturing facility inspection, indicating significant regulatory challenges.

#securities claims #FDA #Biologics License Application #stock price #investor losses

THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality

GlobeNewswire Inc. • Usa News Group

THE EFFICIENCY PARADOX: 5 Market Anomalies Trading Below Reality

12/06/2025 01:51 PM • Market intelligence report highlighting five undervalued companies across biotech, AI, defense, gold exploration, and medical technology sectors, suggesting significant potential for valuation growth due to technological innovations and strategic positioning.

AMD - Experienced significant stock price decline as part of broader AI stock selloff
ONCY - Developing innovative cancer immunotherapy with promising Phase 3 trial design, FDA alignment, and partnerships with major pharmaceutical companies

#biotech #AI #defense technology #gold exploration #medical diagnostics #small-cap investing

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

AGL Investor News: If You Have Suffered Losses in agilon health, inc. (NYSE: AGL), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

12/06/2025 01:36 PM • Rosen Law Firm is investigating potential securities claims for agilon health shareholders after the company suspended its 2025 financial guidance, causing a 51.5% stock price drop on August 5, 2025.

PLTR - Dropped as part of the broader technology and AI stock market decline
AGL - Company suspended full-year financial guidance, acknowledged more severe industry headwinds than previously expected, and experienced a significant 51.5% stock price decline

#securities claims #investor losses #financial guidance #stock price drop

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—WBD, TRUE, CMA, and FITB

GlobeNewswire Inc. • Juan Monteverde

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—WBD, TRUE, CMA, and FITB

12/06/2025 01:00 PM • Law firm Monteverde & Associates is investigating several corporate mergers and acquisitions, including transactions involving Warner Bros. Discovery, trueCar, Comerica, and Fifth Third Bancorp.

WBD - Potential sale to Netflix with defined share and cash exchange terms

#mergers #acquisitions #shareholder #class action #investigation

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—TBHC, BLFY, SOUL, and SNCR

GlobeNewswire Inc. • Juan Monteverde

$HAREHOLDER ALERT: The M&A Class Action Firm Is Investigating the Merger—TBHC, BLFY, SOUL, and SNCR

12/06/2025 01:00 PM • Law firm Monteverde & Associates is investigating several corporate mergers involving technology, banking, and acquisition companies, offering shareholders potential legal recourse.

TBHC - Proposed sale to Bed Bath & Beyond with defined stock exchange ratio

#merger #shareholder #class action #investigation

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

GlobeNewswire Inc. • Reed Kathrein

ATYR Lawsuit: Hagens Berman Urges aTyr Pharma Investors to Act by Dec. 8 Deadline in Suit Over Trial Failure

12/06/2025 12:58 PM • Hagens Berman is pursuing a securities class action lawsuit against aTyr Pharma after its flagship drug trial failed, causing an 83% stock price collapse. The lawsuit alleges the company misrepresented the efficacy of its drug Efzofitimod and concealed material adverse facts about its performance.

ATYR - Stock collapsed 83% after drug trial failure, facing lawsuit alleging misleading investors about drug efficacy, potential securities law violations

#securities lawsuit #drug trial #pharmaceutical #investor rights #clinical trial

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

GlobeNewswire Inc. • Rosen Law Firm

TNDM Investor News: If You Have Suffered Losses in Tandem Diabetes Care, Inc. (NASDAQ: TNDM), You Are Encouraged to Contact The Rosen Law Firm About Your Rights

12/06/2025 12:53 PM • Rosen Law Firm is investigating potential securities claims for Tandem Diabetes Care shareholders following a voluntary medical device correction that caused a significant stock price drop.

TNDM - Company issued a voluntary medical device correction for t:slim X2 insulin pumps that triggered a 19.9% stock price decline, indicating potential product reliability issues and investor concern

#securities claim #medical device #stock drop #investor losses

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

GlobeNewswire Inc. • Prelude Therapeutics

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

12/06/2025 11:00 AM • Prelude Therapeutics presented preclinical data on two promising therapeutic approaches for myeloproliferative neoplasms (MPNs): a JAK2V617F-selective JH2 inhibitor (PRT12396) and a mutant calreticulin targeted degrader antibody conjugate, demonstrating potential disease-modifying capabilities.

AMZN - Dropped as a major customer, perceived as focusing on cost-cutting rather than comprehensive employee benefits
PRLD - Company presented promising preclinical data for two novel therapeutic approaches, completed toxicology studies, and is on track to file an IND in Q1 2026, indicating strong scientific progress and potential for innovative treatments

#myeloproliferative neoplasms #JAK2V617F #precision oncology #targeted therapy #antibody drug conjugate

Why Bloom Energy Stock Sank 17.3% In November

The Motley Fool • Brett Schafer

Why Bloom Energy Stock Sank 17.3% In November

12/06/2025 10:37 AM • Bloom Energy experienced a stock decline in November due to broader AI sector sentiment shifts, despite strong growth potential in AI infrastructure energy solutions and a significant Brookfield partnership.

BE - Stock fell 17.3% in November but shows recovery potential; has strong revenue growth (129% in 5 years) but considered overvalued with thin profit margins

#fuel cell #AI infrastructure #energy technology #electricity generation

Can Home Depot (HD) Stock Rebound in 2026?

The Motley Fool • Jennifer Saibil

Can Home Depot (HD) Stock Rebound in 2026?

12/06/2025 10:35 AM • Home Depot is experiencing challenges due to a suppressed real estate market and reduced consumer discretionary spending, with declining sales and earnings. Despite these challenges, the company is focusing on internal improvements and maintaining its dividend.

PFE - Initiated the challenge against BridgeBio's advertising claims through proper regulatory channels
HD - Stock is down 17% year-to-date, experiencing sales and earnings pressure due to high interest rates and reduced consumer spending on home improvement products. Management lowered full-year expectations for comparable sales and operating margin.

#home improvement #real estate market #discretionary spending #dividend #market share

Here's Why Shares in This Nvidia Partner Soared This Week

The Motley Fool • Lee Samaha

Here's Why Shares in This Nvidia Partner Soared This Week

12/06/2025 10:33 AM • Synopsys stock rose 11.7% after announcing an expanded strategic partnership with Nvidia, which involved a $2 billion investment. The partnership aims to enhance chip design and engineering simulation capabilities across multiple industries.

SNPS - Stock rose 11.7% due to strategic partnership with Nvidia, $2 billion investment, and potential expansion of total addressable market through Ansys acquisition

#AI #chip design #semiconductor #partnership #investment

PRGO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Perrigo Company plc Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

GlobeNewswire Inc. • Robbins Geller Rudman & Dowd Llp

PRGO INVESTOR ALERT: Robbins Geller Rudman & Dowd LLP Announces that Perrigo Company plc Investors with Substantial Losses Have Opportunity to Lead Investor Class Action Lawsuit

12/06/2025 09:50 AM • Perrigo faces class action lawsuit alleging misleading statements about its infant formula business acquisition, with claims of significant underinvestment, manufacturing deficiencies, and overstated financial results.

BBAI.WS - Stock down 21.2%, negative earnings of $450 million in last 12 months, sales decreased 18.4% year-over-year, high price-to-sales ratio of over 13
PRGO - Multiple disclosures of financial challenges, including 50% earnings decline, significant remediation costs, reduced sales, decreased gross margins, and strategic review of infant formula business indicating substantial operational and financial problems

#securities fraud #infant formula #class action lawsuit #investor alert

System Infrastructure Software Market to Reach USD 297.18 Billion by 2032, Growing at a CAGR of 7.12% | Research by SNS Insider

GlobeNewswire Inc. • Sns Insider

System Infrastructure Software Market to Reach USD 297.18 Billion by 2032, Growing at a CAGR of 7.12% | Research by SNS Insider

12/06/2025 09:45 AM • The system infrastructure software market is projected to grow from USD 161 billion in 2023 to USD 297.18 billion by 2032, driven by cloud adoption, digital transformation, and increasing demand for scalable IT management solutions.

PLTR - Mentioned in article but no specific negative or positive analysis provided
AMZN - Expanding collaboration with NVIDIA to enhance generative AI infrastructure, indicating technological leadership and innovation

#system infrastructure software #cloud computing #digital transformation #multi-cloud strategy #IT management

META, NFLX, CRM, And More: 5 Stocks That Dominated Investor Buzz This Week

Benzinga • Rishabh Mishra

META, NFLX, CRM, And More: 5 Stocks That Dominated Investor Buzz This Week

12/06/2025 09:30 AM • Retail investors focused on five tech stocks this week, driven by earnings reports, AI developments, and corporate news across social networking, software, streaming, and automotive sectors.

META - Faced EU antitrust probe but made strategic moves in AI, with budget cuts to metaverse and hiring Apple designer

#earnings #AI #tech stocks #retail investors #market trends

ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds aTyr Investors to Contact the Firm Before December 8th Regarding Their Rights

GlobeNewswire Inc. • Bragar Eagel & Squire, P.C.

ATYR CLASS ACTION DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds aTyr Investors to Contact the Firm Before December 8th Regarding Their Rights

12/06/2025 08:53 AM • A class action lawsuit has been filed against aTyr Pharma alleging false and misleading statements about the efficacy of their drug Efzofitimod, with investors having until December 8, 2025 to apply as lead plaintiff.

ATYR - The lawsuit alleges the company made materially false statements about their drug's capabilities, potentially misleading investors and causing artificial inflation of stock prices

#class action #lawsuit #securities #pharmaceutical #investor rights

CBD Nutraceuticals Market Projected to Reach USD 39.06 Billion by 2032 at 16.38% CAGR – SNS Insider

GlobeNewswire Inc. • Sns Insider

CBD Nutraceuticals Market Projected to Reach USD 39.06 Billion by 2032 at 16.38% CAGR – SNS Insider

12/06/2025 08:45 AM • The CBD nutraceuticals market is projected to grow from $9.75 billion in 2023 to $39.06 billion by 2032, driven by increasing consumer interest in natural wellness solutions and gradual product legalization.

CVSI - Acquired Elevated Softgels LLC, enhancing global presence in CBD nutraceuticals industry

#CBD #nutraceuticals #wellness #natural health #market growth

K-Shaped Growth And Policy Volatility, JP Morgan's 2026 Outlook

Benzinga • Stjepan Kalinic

K-Shaped Growth And Policy Volatility, JP Morgan's 2026 Outlook

12/06/2025 08:43 AM • JP Morgan predicts a K-shaped economic growth in 2026, with uneven market performance driven by policy factors like tariffs, immigration, and AI investments. The bank expects continued U.S. economic expansion with moderate inflation and cautious interest rate adjustments.

IEMG - JP Morgan suggests potential for international market rotation, with emerging markets offering attractive investment opportunities

#K-shaped growth #economic outlook #AI investment #tariffs #interest rates

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – STUB

GlobeNewswire Inc. • Rosen Law Firm

ROSEN, A TRUSTED AND LEADING LAW FIRM, Encourages StubHub Holdings, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – STUB

12/06/2025 08:34 AM • Rosen Law Firm alerts StubHub Holdings investors about a potential securities class action lawsuit alleging misleading financial statements related to vendor payment timing and free cash flow impacts, with a lead plaintiff deadline of January 23, 2026.

STUB - The lawsuit alleges the company's registration statement was materially false and misleading, suggesting potential financial misrepresentation and potential investor damages

#securities class action #IPO #investor rights #financial disclosure

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

GlobeNewswire Inc. • Disc Medicine

Disc Medicine Presents Positive Initial Data from RALLY-MF Phase 2 Trial in Patients with Myelofibrosis (MF) and Anemia at the 67th American Society of Hematology (ASH) Annual Meeting

12/06/2025 08:00 AM • Disc Medicine reported promising results from its Phase 2 trial of DISC-0974 for treating anemia in myelofibrosis patients, demonstrating substantial hematologic responses across different patient subgroups and transfusion statuses.

GOOGL - Strong cloud revenue growth (34% YoY), profitable cloud business, top-performing AI model, trading at attractive valuation, and significant stock price recovery
IRON - Presented strong clinical trial results showing meaningful anemia responses, reduced transfusion burden, and potential for addressing an unmet medical need in myelofibrosis treatment

#myelofibrosis #anemia #clinical trial #hematology #DISC-0974

Canada’s Tenth Costco Business Centre is now open in East Gwillimbury

GlobeNewswire Inc. • Marc-André Bally

Canada’s Tenth Costco Business Centre is now open in East Gwillimbury

12/06/2025 08:00 AM • Costco Wholesale opened its tenth Canadian Business Centre in East Gwillimbury, Ontario, creating 240 local jobs and offering over 3,000 unique business-focused products. The 137,000 square-foot facility provides specialized items for restaurants, stores, and offices, with next-day delivery and extended business hours.

COST - Expanding business operations, creating local jobs, introducing new business-focused service model, demonstrating growth and strategic market expansion

#business centre #retail #job creation #commercial products #warehouse

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

GlobeNewswire Inc. • Bicara Therapeutics

Bicara Therapeutics’ Preliminary Phase 1b Expansion Cohort Data Evaluating 750mg of Ficerafusp Alfa Weekly Plus Pembrolizumab Advances Pivotal Study Dose Selection on Track for First Quarter 2026

12/06/2025 08:00 AM • Bicara Therapeutics reported promising Phase 1b data for ficerafusp alfa, a bifunctional antibody, in treating HPV-negative head and neck squamous cell carcinoma. The 750mg weekly dose showed a 57% confirmed overall response rate and was well-tolerated when combined with pembrolizumab.

GLW - Partnered with QuantumScape to develop ceramic battery separators, indicating potential for future collaboration
BCAX - Demonstrated promising clinical trial results with a 57% overall response rate, consistent safety profile, and potential for meaningful patient outcomes in head and neck cancer treatment

#ficerafusp alfa #head and neck cancer #immunotherapy #clinical trials #TGF-β inhibition

Carbon Credit Trading Platform Market Size to Exceed USD 1513.44 Million by 2033, at 25% CAGR | SNS Insider

GlobeNewswire Inc. • Sns Insider

Carbon Credit Trading Platform Market Size to Exceed USD 1513.44 Million by 2033, at 25% CAGR | SNS Insider

12/06/2025 08:00 AM • The carbon credit trading platform market is projected to grow from USD 253.91 million in 2025 to USD 1513.44 million by 2033, driven by stricter emission regulations, corporate net-zero goals, and increasing demand for digital carbon credit transactions.

VWAGY - Actively partnering with QuantumScape, planning field tests of electric motorcycle with new battery technology
NDAQ - Projected significant growth in carbon offset demand, with potential market worth up to USD 50 billion by 2030

#carbon credits #carbon trading #sustainability #emissions reduction #net-zero

GlobeNewswire Inc. • Beam Therapeutics

Beam Therapeutics Reports Updated Data from BEACON Phase 1/2 Trial of ristoglogene autogetemcel (risto-cel) Highlighting Durable, Differentiated Profile in Sickle Cell Disease (SCD) at American Society of Hematology (ASH) Annual Meeting

12/06/2025 08:00 AM • Beam Therapeutics presented promising clinical trial results for risto-cel, a base editing cell therapy for sickle cell disease, showing high hemoglobin F induction, reduced hemoglobin S, and durable anemia resolution in 31 patients.

BEAM - Reported strong clinical trial results with high editing efficiency, rapid patient engraftment, and no severe vaso-occlusive crises, indicating promising progress in developing a potential transformative therapy for sickle cell disease

#sickle cell disease #base editing #genetic medicine #clinical trial #hemoglobin

1 Risky ETF You Want to Avoid Buying in December

The Motley Fool • Stefon Walters

1 Risky ETF You Want to Avoid Buying in December

12/06/2025 07:33 AM • The Vanguard Information Technology ETF (VGT) has performed well in 2023, but carries high risk due to extreme concentration in three major tech stocks: Nvidia, Apple, and Microsoft, which collectively represent over 45% of the ETF's holdings.

VGT - High concentration risk with top 3 stocks representing over 45% of ETF, making it vulnerable to performance fluctuations

#ETF #technology #market concentration #investment risk

Stormwater Detention System Market Size to Hit USD 876.02 Million by 2033 | Research by SNS Insider

GlobeNewswire Inc. • Sns Insider

Stormwater Detention System Market Size to Hit USD 876.02 Million by 2033 | Research by SNS Insider

12/06/2025 07:00 AM • The global stormwater detention system market is projected to grow from $592.92 million in 2025 to $876.02 million by 2033, driven by urbanization, flood prevention needs, and sustainable drainage solutions.

FFWM - Being acquired by FirstSun Capital Bancorp through share exchange, potential investigation implies possible examination of transaction fairness
WMS - Introducing innovative eco-pure biofilter solutions for urban stormwater management, demonstrating technological advancement and market adaptability

#stormwater management #urban infrastructure #flood prevention #sustainable drainage